Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuropeptides. Function and clinical applications.

J Hughes1, G N Woodruff

  • 1Parke-Davis Neuroscience Research Centre, Addenbrookes Hospital Site, Cambridge, United Kingdom.

Arzneimittel-Forschung
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concurrent chronic administration of a CCK(B) antagonist can decrease tolerance to the ataxic effects of ethanol.

Addiction biology·2010
Same author

Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·1998
Same author

Spermine modulation of specific [3H]-gabapentin binding to the detergent-solubilized porcine cerebral cortex alpha 2 delta calcium channel subunit.

British journal of pharmacology·1997
Same author

Anticonvulsant effect of reduced NMDA receptor expression in audiogenic DBA/2 mice.

Epilepsy research·1996
Same author

The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine.

Psychopharmacology·1996
Same author

The influence of guanyl nucleotide on agonist and antagonist affinity at guinea-pig CCK-B/gastrin receptors: binding studies using [3H]PD140376.

Regulatory peptides·1996
Same journal

Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

Arzneimittel-Forschung·2013
Same journal

Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

Arzneimittel-Forschung·2013
Same journal

Leave-one-out procedure in the validation of elimination rate constant analysis.

Arzneimittel-Forschung·2012
Same journal

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Arzneimittel-Forschung·2012
Same journal

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Arzneimittel-Forschung·2012
Same journal

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Arzneimittel-Forschung·2012
See all related articles

Novel peptoid drugs, mimicking or blocking neuropeptide actions, offer targeted treatments for brain conditions. These compounds show greater selectivity and fewer side effects than traditional drugs, with potential for pain, stroke, anxiety, and drug abuse therapies.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Neuropeptides are key brain messengers modulating neurotransmission.
  • Their presynaptic function allows for highly adaptable neuromodulation.
  • Neuropeptide systems are activated under specific conditions.

Purpose of the Study:

  • To explore the therapeutic potential of novel peptoid drugs.
  • To investigate the selectivity and efficacy of peptoids compared to traditional compounds.
  • To understand the role of neuropeptide systems in neurological and psychiatric disorders.

Main Methods:

  • Development of novel peptoid drugs mimicking or blocking neuropeptide function.
  • Evaluation of kappa opioid-receptor agonists (e.g., CI-977) for pain and stroke.

Related Experiment Videos

  • Assessment of cholecystokinin B (CCK-B) antagonists (e.g., CI-988) for anxiety and drug abuse.

    • Main Results:

    • Peptoids demonstrate enhanced selectivity compared to amino acid/amine-based drugs.
    • Peptoid antagonists show a favorable side-effect profile.
    • Peptoid agonists can exert potent effects on brain function due to receptor hierarchy.

    Conclusions:

    • Peptoids represent a promising class of drugs for neurological and psychiatric conditions.
    • Targeting neuropeptide systems with peptoids offers new clinical strategies.
    • The selectivity of peptoids may lead to improved therapeutic outcomes with reduced adverse effects.